Anavex Life Sciences Corp (AVXL)

[Gator328]

You have some fair points, but allow me to offer a bit of perspective as I too have been invested in Anavex since the early days, pre-CTAD 2015.

1. What does it benefit Dr. Missling to report more information at this point? No matter what he does, there will be those who call him a liar and accuse him of bending the statistics and we'll see more short attacks fueled by hit pieces from the likes of Adam Feuerstein.

2. There could be strategic reasons for the delays. Many years ago I was involved in a situation where I had access to insider information. Shareholders were frustrated. I wanted to post all that I knew online, but the lawyers made it clear that I was to remain silent. Over the 2.5 year period, I saw a lot of shareholders bail. The patient ones were rewarded with 5000% gains. I'm not saying there's a strategic reason why Dr. Missling isn't providing timely data, but it could be that his hands are tied by the legal department.

3. A $600 million market cap for a company that doesn't have any products for sale, with zero guarantees that it ever will, is pretty impressive, especially at a time when investors are as risk-averse as they have been in a decade. If and when Blarcamesine reaches market and outperforms the current standard of care, it'll be possible for analysts to construct appropriate cash flow models, apply their own discount rate and determine an appropriate valuation. The stock price should eventually reach this market cap as this company transitions from 40% to 85% institutionally owned.

I think at this point, Dr. Missling is content to stay quiet, present the bare minimum to the public, and let the FDA be the final arbiter over whether the trials were successful.